<PAGE>


                                                                    Exhibit 99.3

MIVT ANNOUNCES NSERC RESEARCH GRANT
MIV THERAPEUTICS ANNOUNCES NSERC GRANT FOR HYDROXYAPATITE COATED STENT
DEVELOPMENT VANCOUVER, B.C. Feb 10, 2003

MIV Therapeutics Inc. (MIVT:OTCBB) and the University of British Columbia (UBC)
are pleased to announce that the Natural Sciences and Engineering Research
Council of Canada (NSERC) has awarded Dr. Tom Troczynski a one year
Collaborative Research and Development (CRD) grant to develop hydroxyapatite
coatings for stainless steel stents. The program is titled "Functionally
Gradient Calcium Phosphate Coatings for Stents". The NSERC CRD grant follows a
year and a half of contract research done by Dr. Troczynski. The research was
conducted at UBC and funded by MIVT.

Dr. Tom Troczynski, PhD, P.Eng is a Professor in Metals and Materials
Engineering Dept. at the University of British Columbia and leads UBCeram, one
of the largest ceramics research groups in Canada. His bio-ceramics development
program is focused on the development of biocompatible hydroxyapatite coatings
for metallic substrates, such as implants and stents. Dr. Tom Troczynski was
appointed as MIVT Vice President of Coating Technologies in February 2002, in
order to assist in the development of its proprietary coating technologies and
to transfer UBC technology to MIVT.

NSERC is Canada's national instrument for making strategic investments in
science and technology. It fulfills its mission by awarding scholarships and
research grants through peer-reviewed competition and by building partnerships
among universities, colleges, governments and the private sector.

"Grants received from NSERC are critical to the development of our program and
an indicator of the validity of our research," says Troczynski. "Innovative
companies like MIVT need to be cultivated in their development by infusing
research with commercial applications." President and CEO, Alan Lindsay, states
"The drug-eluting stent industry is showing itself to be one which can change
dramatically in a relatively short period of time. Recent developments among
current competitors suggest to us that this is an opportune time for an
increased focus on our biocompatible coating program. Hydroxyapatite (HAp), is
known to be an excellent bio- compatible and bio-active material. We intend to
continue our thin-coat development and, with the help of this grant, further
develop multi-layer coatings which can encapsulate drugs designed to prevent
restenosis (the re- narrowing of arteries after angioplasty)".

ABOUT UNIVERSITY OF BRITISH COLUMBIA
UBC, located in the Pacific Rim gateway of Vancouver, Canada, ranks in the top
10 of North American universities in technology licensing and commercialization,
and generates more U.S. patent applications than any other Canadian public
institution.

<PAGE>

ABOUT MIV THERAPEUTICS
MIV Therapeutics is developing a "next generation" line of advanced
biocompatible stent coatings and therapeutics for stent-based drug-delivery
systems. The Company has completed development of a line of proprietary coronary
stents for use in angioplasty procedures and is in late-stage development of its
hydroxyapatite stent coating technology, licensed from the University of British
Columbia. In addition, MIVT has an exclusive worldwide licensing agreement for
the use in manufacturing, distribution and marketing of Endovasc's PROStent(TM)
drug-eluting stent. MIVT's manufacturing facility maintains a comprehensive QA
(Quality Assurance) system which meets the guidelines of ISO 9001 (1994) and ISO
13485 (1996) requirements, complies with applicable FDA guidelines and
applicable GMP requirements and is capable of private label manufacturing and
out sourcing.
Please visit our new web site at www.mivtherapeutics.com

FOR FURTHER INFORMATION:
Daniel Byrne
Investor Relations
(888) 998-8886
dbyrne@mivtherapeutics.com

Craig Scott
Director of Investor Relations
800-769-7205 or 303-843-6191
craigscott@mivtherapeutics.com

FOR PRODUCT INQUIRIES AND BUSINESS OPPORTUNITIES:
Arc Rajtar
(604) 301-9545 ext 22
arajtar@mivi.ca

EXCEPT FOR THE HISTORICAL INFORMATION CONTAINED HEREIN, THE MATTERS DISCUSSED IN
THIS PRESS RELEASE ARE FORWARD-LOOKING STATEMENTS. SUCH STATEMENTS ARE INDICATED
BY WORDS OR PHRASES SUCH AS "CAN," "SUGGEST," AND "INTEND." THESE STATEMENTS ARE
MADE UNDER THE "SAFE HARBOR" PROVISIONS OF THE PRIVATE SECURITIES LITIGATION
REFORM ACT OF 1995. ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE DESCRIBED IN
FORWARD- LOOKING STATEMENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES. PLEASE
SEE THE COMPANY'S FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION INCLUDING,
WITHOUT LIMITATION, THE COMPANY'S RECENT FORM 10-K AND FORM 10-QS, WHICH
IDENTIFY SPECIFIC FACTORS THAT MAY CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER
MATERIALLY FROM THOSE DESCRIBED IN THE FORWARD-LOOKING STATEMENTS.